Key clinical point: The LDL cholesterol–lowering response to PCSK9 inhibition is highly variable in adults with homozygous familial hypercholesterolemia.

Major finding: Twelve weeks of alirocumab achieved a mean 63-mg/dL reduction in LDL cholesterol in adults with homozygous familial hypercholesterolemia.

Study details: ODYSSEY HoFH was a 12-week, randomized, placebo-controlled, double-blind study including 69 adults with homozygous familial hypercholesterolemia.

Disclosures: ODYSSEY HoFH was sponsored by Regeneron and Sanofi. The presenter reported serving as a paid consultant to Sanofi, Akcea, Amgen, and Gemphire.